Straumann starts 2026 with solid organic growth and reaffirms outlook

Straumann Holding AG ( (CH:STMN) ) has shared an update.

Straumann Group opened 2026 with first-quarter revenue of CHF 673 million, representing 7.1% organic growth but a 1.2% decline in Swiss franc terms due to adverse currency effects. Growth was broadly based across regions and business lines, led by implantology demand, robust uptake of digital solutions such as intraoral scanners and the Straumann AXS platform, and strong customer engagement through training and education.

The company further consolidated its leading implantology position via the rollout of its premium iEXCEL system, global expansion of its challenger brand Neodent and support from the newly launched AOMI specialist network. EMEA and Latin America delivered strong double-digit or high single-digit growth, North America continued to outperform its market, and Asia-Pacific grew solidly when excluding a still-normalizing China, while management reaffirmed its 2026 guidance for high single-digit organic revenue growth and a modest core EBIT margin improvement, signalling confidence in strategy execution despite a volatile macro environment and lingering currency headwinds.

The most recent analyst rating on (CH:STMN) stock is a Sell with a CHF83.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

More about Straumann Holding AG

Straumann Holding AG, headquartered in Basel, operates in the dental-medtech industry, focusing on implantology, orthodontics and digital dentistry solutions. Its portfolio spans premium and challenger dental implants, clear aligners, intraoral scanners and digital workflow platforms, with a global market presence across EMEA, North America, Asia-Pacific and Latin America.

Average Trading Volume: 445,644

Technical Sentiment Signal: Sell

Current Market Cap: CHF13.39B

See more insights into STMN stock on TipRanks’ Stock Analysis page.